Primary hypercholesterolaemia is a disorder where too much low-density lipoprotein cholesterol (LDL-C), often called “bad cholesterol,” accumulates in the blood, increasing the risk of heart attack and stroke. Treatment aims to reduce cholesterol levels and prevent serious cardiovascular complications through a combination of lifestyle changes, proven medications, and in some cases, innovative therapies currently being tested in clinical trials.

Understanding Treatment Goals for High Cholesterol

When doctors diagnose primary hypercholesterolaemia, their main goal is not simply to lower numbers on a test result. The real purpose is to reduce the chance that fat and cholesterol will build up inside the walls of arteries, a process called atherosclerosis. This buildup narrows blood vessels over time, making it harder for blood to flow freely. If a blood vessel becomes too narrow or blocked, the heart or brain may not receive enough oxygen-rich blood. The result can be a heart attack, stroke, or other serious cardiovascular events that can cause long-term disability or even death.^[1][4]

The approach to treating hypercholesterolaemia depends heavily on how much risk a person faces. A young person with no other health problems and only mildly elevated cholesterol might need only lifestyle adjustments. On the other hand, someone who has already had a heart attack, or who has diabetes, high blood pressure, and a family history of early heart disease, needs more aggressive treatment. Medical guidelines from the United States, United Kingdom, Canada, and Europe all agree that the first step is to assess a person’s overall cardiovascular risk before deciding how intensely to treat cholesterol levels.^[2][4]

Treatment is tailored to each individual. Factors such as age, sex, smoking status, presence of diabetes, and family history all play a role in determining the best course of action. The aim is to bring LDL cholesterol down to a level that significantly reduces the chance of a future cardiovascular event, while balancing the benefits of treatment against potential side effects and costs.^[10][15]

Modern medicine has made great progress in understanding that lowering LDL cholesterol can save lives. Decades of research, including large randomized clinical trials and genetic studies, have consistently shown that reducing LDL cholesterol levels lowers the risk of heart disease and stroke. The lower the cholesterol, and the longer it stays low, the greater the benefit. This principle guides both standard treatment with approved drugs and ongoing research into new therapies being tested in clinical trials.^[15]

Standard Treatment for Primary Hypercholesterolaemia

The foundation of all cholesterol treatment is making changes to daily habits. Doctors call this approach therapeutic lifestyle changes, or TLC. It involves eating differently, moving more, quitting smoking, and managing weight. Even though medications are often necessary, lifestyle changes remain essential because they improve overall health, help medications work better, and may reduce the doses needed.^[5][12]

A heart-healthy diet focuses on reducing the amount of saturated fat and trans fat in food. Saturated fats are found mainly in red meat, full-fat dairy products like butter and cheese, and certain tropical oils such as palm oil. Trans fats appear in many processed foods, margarines, and baked goods, though regulations in many countries have led manufacturers to reduce or eliminate them. When people eat too much of these fats, the liver struggles to remove cholesterol from the blood, and LDL levels rise.^[3][16]

Instead, the diet should include foods rich in soluble fiber, such as oatmeal, beans, lentils, apples, pears, and barley. Soluble fiber helps reduce the absorption of cholesterol in the intestines. Adding foods that contain plant stanols and sterols—natural compounds found in whole grains, nuts, seeds, and certain vegetable oils—can also help lower LDL cholesterol. Eating fatty fish like salmon, mackerel, or herring provides omega-3 fatty acids, which may not directly lower LDL but offer other heart-protective benefits, such as reducing inflammation and improving blood vessel function.^[16][22]

Physical activity is another pillar of cholesterol management. Regular exercise helps raise levels of HDL cholesterol, often called “good cholesterol,” which helps remove excess cholesterol from the bloodstream. Exercise also helps with weight control, lowers blood pressure, and improves insulin sensitivity. Guidelines recommend at least 150 minutes of moderate-intensity exercise per week for adults, such as brisk walking, cycling, or swimming.^[18][20]

Quitting smoking is critical. Smoking damages blood vessels, speeds up the hardening of arteries, and makes it easier for cholesterol to stick to artery walls. It also lowers HDL cholesterol. People who stop smoking significantly reduce their cardiovascular risk, and this benefit is independent of cholesterol levels.^[8][18]

For many people, however, lifestyle changes alone are not enough to bring cholesterol down to safe levels. This is especially true for those with very high LDL cholesterol, such as people with familial hypercholesterolaemia, a genetic condition that causes severely elevated cholesterol from birth, or for people who already have cardiovascular disease. In these cases, medication is necessary.^[6][13]

The most widely used and most effective cholesterol-lowering medications are statins. Statins work by blocking an enzyme in the liver called HMG-CoA reductase, which the body needs to make cholesterol. When cholesterol production drops, the liver responds by increasing the number of LDL receptors on its surface. These receptors pull LDL cholesterol out of the bloodstream, lowering blood levels significantly. Commonly prescribed statins include atorvastatin, rosuvastatin, simvastatin, pravastatin, and lovastatin.^[14][15]

Statins have been studied in hundreds of clinical trials involving hundreds of thousands of patients. The evidence is clear: statins reduce the risk of heart attack, stroke, and death from cardiovascular causes in both people who have already had a cardiovascular event (secondary prevention) and those at high risk who have not yet had an event (primary prevention). The benefits are dose-related—higher doses lower cholesterol more and provide greater risk reduction.^[14][15]

Treatment with statins is usually long-term, often lifelong. Doctors monitor cholesterol levels regularly, typically every few months when treatment begins, and then annually once levels stabilize. The goal is to achieve target LDL cholesterol levels based on the person’s cardiovascular risk. For people at very high risk, such as those who have had a recent heart attack, the target may be less than 70 mg/dL. For those at lower risk, a target below 100 or 130 mg/dL may be appropriate.^[9][10]

Like all medications, statins can cause side effects. The most common complaints are muscle aches and pains, which affect a small percentage of users. Rarely, statins can cause more serious muscle damage or liver enzyme elevations, so doctors may order blood tests to monitor liver function. Some people also report digestive upset or headaches. Most side effects are mild and go away when the dose is adjusted or a different statin is tried. The benefits of statins in preventing heart attacks and strokes generally far outweigh these risks for most people.^[14][19]

When statins alone do not lower cholesterol enough, or when a person cannot tolerate statins, doctors may add other medications. Ezetimibe is a drug that works in the intestines to block the absorption of cholesterol from food. It can be used alone or combined with a statin. Adding ezetimibe to statin therapy can lower LDL cholesterol by an additional 15 to 20%. However, studies have shown that while ezetimibe lowers cholesterol levels, its impact on reducing heart attacks and strokes is less clear than with statins.^[14]

Bile acid-binding resins, such as cholestyramine and colesevelam, are older drugs that work by binding to bile acids in the intestines. Since bile acids are made from cholesterol, the liver must use more cholesterol to make new bile acids, which lowers blood cholesterol. These medications can cause digestive side effects like bloating, constipation, and gas, which can make them difficult for some people to tolerate.^[14]

Niacin, a form of vitamin B3, can raise HDL cholesterol and lower LDL cholesterol and triglycerides (another type of blood fat). However, niacin often causes flushing, itching, and stomach upset. More importantly, clinical trials have not consistently shown that niacin reduces the risk of heart attacks or strokes when added to statin therapy, so it is not commonly recommended.^[14]

Fibrates, such as gemfibrozil and fenofibrate, are mainly used to lower triglycerides and can modestly raise HDL cholesterol. They are sometimes prescribed for people with very high triglyceride levels or those with low HDL cholesterol. Like niacin, fibrates have not been proven to consistently reduce cardiovascular events when added to statins, so their use is selective.^[14]

Bempedoic acid is a newer medication that, like statins, works in the liver to reduce cholesterol production. It can be used alone or with other drugs. Because it is activated only in the liver and not in muscles, it may cause fewer muscle-related side effects than statins. Clinical trials have shown that bempedoic acid effectively lowers LDL cholesterol, though long-term data on its impact on cardiovascular outcomes are still being gathered.^[10]

For people with very severe hypercholesterolaemia who do not respond adequately to medications, more intensive treatments may be needed. LDL apheresis is a procedure similar to dialysis, where blood is filtered to remove LDL cholesterol. It is used in rare cases, such as severe familial hypercholesterolaemia. In extremely rare and severe cases, liver transplantation has been considered, since the liver is the main organ responsible for cholesterol regulation.^[7]

Innovative Treatments in Clinical Trials

While standard treatments have proven effective, researchers continue to explore new ways to lower cholesterol and reduce cardiovascular risk. Some of the most promising advances involve a new class of drugs called PCSK9 inhibitors. These are biological therapies, usually given by injection every two to four weeks. PCSK9 is a protein that reduces the number of LDL receptors on liver cells, making it harder for the liver to remove cholesterol from the blood. By blocking PCSK9, these drugs increase the number of receptors and dramatically lower LDL cholesterol levels.^[10][15]

Two PCSK9 inhibitors, evolocumab and alirocumab, have been tested in large Phase III clinical trials involving thousands of patients. These studies showed that PCSK9 inhibitors can lower LDL cholesterol by 50 to 60% or more, even in people already taking statins. Importantly, clinical trials have demonstrated that these drugs reduce the risk of heart attack, stroke, and cardiovascular death. They are now approved and used primarily in people with very high cholesterol who cannot reach their targets with statins and other medications, or in those with familial hypercholesterolaemia.^[15]

Another innovative approach involves a drug called inclisiran, which uses a technology called RNA interference (RNAi). Inclisiran works by reducing the production of the PCSK9 protein in the liver. One of its major advantages is that it only needs to be injected twice a year, compared to the more frequent injections required by other PCSK9 inhibitors. Phase III trials have shown that inclisiran effectively lowers LDL cholesterol, and it has been approved in several countries, including in Europe and the United States.^[15]

Researchers are also investigating treatments that target other molecules involved in cholesterol metabolism. For example, drugs that inhibit angiopoietin-like protein 3 (ANGPTL3) are being tested. ANGPTL3 is involved in regulating lipid levels, and blocking it can lower LDL cholesterol, triglycerides, and other harmful lipids. Some of these therapies are in Phase II trials, where researchers assess their effectiveness and safety in larger groups of patients.^[15]

Another target of interest is lipoprotein(a), or Lp(a), a type of lipoprotein that is largely determined by genetics. High levels of Lp(a) increase cardiovascular risk, but traditional cholesterol-lowering drugs do not effectively lower it. Researchers are developing drugs, including antisense oligonucleotides and small interfering RNA therapies, specifically designed to reduce Lp(a) levels. These treatments are currently in clinical trials, and early results suggest they can significantly lower Lp(a). If proven effective in reducing cardiovascular events, they could offer a new option for people with elevated Lp(a).^[4]

For patients with familial hypercholesterolaemia who cannot tolerate existing medications or whose cholesterol remains dangerously high, clinical trials are exploring combinations of new therapies. Some trials are testing whether combining PCSK9 inhibitors with ezetimibe or bempedoic acid can achieve even greater cholesterol reductions than any single drug alone. Others are looking at whether starting treatment earlier in life, particularly in children with familial hypercholesterolaemia, can prevent the development of atherosclerosis before it becomes severe.^[13]

Clinical trials for new cholesterol treatments are being conducted in many countries, including the United States, Canada, and across Europe. Some trials are also taking place in parts of Asia and other regions. Eligibility for these trials depends on factors such as the person’s cholesterol levels, whether they have cardiovascular disease, their age, and whether they are already taking other cholesterol medications. Patients interested in clinical trials can ask their doctors for information or search online registries that list ongoing studies.^[15]

Most Common Treatment Methods

• Lifestyle Modifications
  • Dietary changes to reduce saturated and trans fats, increase soluble fiber, and add plant stanols and sterols
  • Regular physical activity, such as 150 minutes of moderate exercise per week
  • Weight management to maintain a healthy body weight
  • Smoking cessation to reduce cardiovascular risk
  • Limiting alcohol intake to avoid raising cholesterol and triglyceride levels
• Statin Therapy
  • Statins such as atorvastatin, rosuvastatin, simvastatin, pravastatin, and lovastatin
  • Work by inhibiting HMG-CoA reductase in the liver to reduce cholesterol production
  • Proven to reduce risk of heart attack, stroke, and cardiovascular death
  • Used for both primary and secondary prevention of cardiovascular disease
  • Possible side effects include muscle aches, liver enzyme elevations, and digestive upset
• Cholesterol Absorption Inhibitors
  • Ezetimibe blocks cholesterol absorption in the intestines
  • Can be used alone or combined with statins
  • Provides additional LDL cholesterol reduction of 15 to 20%
• PCSK9 Inhibitors
  • Biological therapies such as evolocumab and alirocumab
  • Block the PCSK9 protein to increase LDL receptors on liver cells
  • Lower LDL cholesterol by 50 to 60% or more
  • Administered by injection every two to four weeks
  • Proven to reduce heart attack, stroke, and cardiovascular death in Phase III trials
• RNA Interference Therapy
  • Inclisiran uses RNA interference to reduce PCSK9 production in the liver
  • Requires injections only twice per year
  • Effective at lowering LDL cholesterol in Phase III trials
• Bempedoic Acid
  • Reduces cholesterol production in the liver
  • May cause fewer muscle-related side effects than statins
  • Can be used alone or in combination with other cholesterol-lowering drugs
• Bile Acid-Binding Resins
  • Medications such as cholestyramine and colesevelam
  • Bind to bile acids in the intestines, forcing the liver to use more cholesterol
  • Can cause digestive side effects like bloating and constipation
• Fibrates
  • Drugs such as gemfibrozil and fenofibrate
  • Mainly used to lower triglycerides and modestly raise HDL cholesterol
  • Not consistently proven to reduce cardiovascular events when added to statins
• Niacin
  • Form of vitamin B3 that can raise HDL cholesterol
  • Often causes flushing, itching, and stomach upset
  • Not commonly recommended due to lack of proven benefit in reducing cardiovascular events
• LDL Apheresis
  • Procedure similar to dialysis that filters LDL cholesterol from the blood
  • Used in rare cases of severe familial hypercholesterolaemia